OTCMKTS:INCPF InnoCare Pharma 8/24/2026 Earnings Report $1.55 0.00 (0.00%) As of 08/14/2026 ProfileForecast InnoCare Pharma EPS ResultsActual EPSN/AConsensus EPS -$0.01Beat/MissN/AOne Year Ago EPSN/AInnoCare Pharma Revenue ResultsActual RevenueN/AExpected Revenue$101.52 millionBeat/MissN/AYoY Revenue GrowthN/AInnoCare Pharma Announcement DetailsQuarterDate8/24/2026TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesCompany Profile InnoCare Pharma Earnings HeadlinesInnoCare Pharma Sets Board Meeting to Approve 2026 Interim ResultsAugust 11, 2026 | tipranks.comChina's Innocare's psoriasis drug meets main goal in late-stage trialJuly 27, 2026 | reuters.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow. | Base Camp Trading (Ad)InnoCare Shareholders Approve All Resolutions at 2026 AGMJune 16, 2026 | tipranks.comPhase IIb Study Results of InnoCare's Orelabrutinib in Patients with SLE Presented at 2026 EULARJune 4, 2026 | globenewswire.comASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML ReleasedJune 2, 2026 | globenewswire.comSee More InnoCare Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like InnoCare Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InnoCare Pharma and other key companies, straight to your email. Email Address About InnoCare PharmaInnoCare Pharma (OTCMKTS:INCPF) Ltd is a China-based, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule targeted therapies for oncology. Headquartered in Shenzhen, Guangdong Province, the company leverages structure-based drug design and comprehensive preclinical screening to advance drug candidates that address high-unmet-need cancers. The company’s development pipeline comprises multiple small-molecule inhibitors in various stages of preclinical and early clinical evaluation. InnoCare has prioritized programs that target solid tumors, including gastrointestinal and other hard-to-treat malignancies. Its research platform integrates in vitro and in vivo models to optimize lead compounds for potency, selectivity and safety. Founded and headquartered in Shenzhen, InnoCare Pharma draws on a multidisciplinary team of medicinal chemists, biologists and clinical development experts. While its initial focus is on serving patients in Greater China, the company is exploring global partnerships and regulatory pathways to extend the reach of its oncology portfolio beyond domestic markets.View InnoCare Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/10 - 08/14Applied Materials Beat Everything but Wall Street’s Expectations for MarginsBack From Orbit, Intuitive Machines' Share Price Enters the Buy ZoneCerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Sandisk’s Margins Look Like Software. Can They Last?AMG’s Alternatives Boom Powers Record Growth Upcoming Earnings Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026)Alibaba Group (8/20/2026)Ross Stores (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
